TROPION-Lung12 phase 3 trial initiated evaluating DATROWAY as part of adjuvant regimen for patients with early-stage Non-Small Cell Lung Cancer at high risk of relapse

CAR-T Digest - August 2020

Weekly Digest - January 2025

30 Jan 2025: TROPION-Lung12 phase 3 trial initiated evaluating DATROWAY as part of adjuvant regimen for patients with early-stage Non-Small Cell Lung Cancer at high risk of relapse

The TROPION-Lung12 phase 3 trial is evaluating the safety and efficacy of adjuvant DATROWAY(datopotamab deruxtecan) with rilvegostomig or rilvegostomig alone versus standard care in stage 1 adenocarcinoma NSCLC patients who are ctDNA-positive or have high-risk features after surgery
Daiichi highlighted that after surgery for early-stage NSCLC, there’s no consensus on adjuvant therapy
TROPION-Lung12 trial aims to explore DATROWAY combined with immunotherapy as a potential treatment to prevent recurrence in high-risk stage 1 adenocarcinoma patients